These are mechanically computed values based on a residual income model. They are not a forecast of market prices or a recommendation of any investment action, and do not predict or guarantee future share prices. Historical values are computed retrospectively using current guidance-achievement statistics.
| Metric | Current Period | Previous Year Period | YoY |
|---|---|---|---|
| Revenue | ¥40.58B | ¥39.18B | +3.6% |
| Operating Income | ¥2.07B | ¥1.86B | +11.5% |
| Ordinary Income | ¥2.24B | ¥2.04B | +10.1% |
| Net Income | ¥1.46B | ¥1.35B | +7.8% |
| ROE | 1.7% | 1.6% | - |
Tokai reported higher revenue and earnings for the quarter, with continued improvement in profitability being the key highlight. Revenue was ¥40.58B (+3.6% YoY), operating income was ¥2.07B (+11.5%), ordinary income was ¥2.24B (+10.1%), and net income attributable to owners of the parent was ¥1.44B (+7.2%). The operating margin improved to 5.1% from 4.7% in the previous year. The fact that earnings growth exceeded revenue growth was driven by higher revenue and earnings in the core HealthyLifeService and improved margins in EcologyService.
【Revenue】Revenue increased 3.6% YoY to ¥40.58B. By segment, HealthyLifeService, which accounts for 52.0% of the revenue mix, led overall growth with a 4.6% increase in revenue, while DispensingService also posted 3.2% growth. EcologyService was nearly flat at -0.3%.
【Profit and Loss】Operating income increased 11.5% to ¥2.07B, while ordinary income increased 10.1% to ¥2.24B, securing earnings growth above the rate of revenue growth. Operating income at HealthyLifeService rose 11.2% to ¥2.04B, with a 9.6% margin, while EcologyService grew 35.8% to ¥0.42B, with an 11.0% margin. In contrast, DispensingService reported a 13.3% decline in operating income to ¥0.299B, with its margin declining to 1.9%, becoming a factor weighing on the company-wide margin. Extraordinary items were limited, comprising extraordinary income of ¥0.02B (gain on sales of investment securities) and extraordinary loss of ¥0.004B (loss on retirement of fixed assets), and the impact of temporary factors was limited. Net income was ¥1.44B after reflecting the tax burden (effective tax rate of approximately 35%), resulting in higher revenue and earnings overall.
HealthyLifeService continued to report higher revenue and earnings as the core business, with revenue of ¥21.198B (+4.6%), operating income of ¥2.043B (+11.2%), and an operating margin of 9.6%. DispensingService posted higher revenue of ¥15.678B (+3.2%), but operating income declined 13.3% to ¥0.299B, with the margin falling to 1.9%, suggesting the impact of the dispensing-fee environment and higher costs. EcologyService was nearly flat in revenue at ¥3.825B (-0.3%), but operating income improved 35.8% to ¥0.421B, with the margin rising to 11.0%, apparently supported by an improved project mix. The significant differences in margins among segments clearly indicate a structure in which HealthyLifeService and EcologyService drive company-wide earnings.
【Profitability】The operating margin improved to 5.1% from 4.7% in the previous year, while the gross margin remained at 24.3%. Meanwhile, the SG&A ratio was 19.2% (SG&A expenses +7.6%), indicating that costs increased at a rate exceeding revenue growth of +3.6%. The net profit margin was 3.5% (net income of ¥1.44B / revenue of ¥40.58B), representing a modest improvement from the previous year.【Cash Flow Quality】Cash and deposits were substantial at ¥26.54B, while accounts receivable were ¥23.59B and inventories were ¥6.79B, both large relative to the asset base, indicating room for improvement in working-capital turnover.【Investment Efficiency】ROE remained low at 1.7%, with low asset turnover relative to total assets of ¥116.60B constraining capital efficiency.【Financial Soundness】The equity ratio was extremely high at 73.2%. With cash and deposits of ¥26.54B against long-term borrowings of ¥0.06B, the financial foundation is conservative and robust.
Although this report does not include detailed cash flow statements, fund movements can be assessed from changes in the balance sheet. Accounts receivable and notes receivable totaled ¥23.59B, while inventories were ¥6.79B, indicating a relatively long period from revenue recognition to cash conversion given the scale of the assets. Short-term borrowings increased from the previous year, indicating rising working-capital requirements. However, cash and deposits of ¥26.54B more than adequately covered short-term liabilities, and funding stability was maintained. Extraordinary items were limited, and the impact of temporary factors distorting the cash conversion of earnings can be assessed as limited.
Current-period earnings were primarily derived from the core business. Extraordinary income of ¥0.02B (gain on sales of investment securities) and extraordinary loss of ¥0.004B (loss on retirement of fixed assets) were both limited, and temporary factors did not materially distort performance. Non-operating income of ¥0.21B consisted mainly of stable items such as dividend income of ¥0.08B and other income of ¥0.04B. At approximately 0.5% of revenue, reliance on non-operating income was low. The difference between ordinary income of ¥2.24B and net income of ¥1.44B was attributable to the tax burden, with an effective tax rate of approximately 35%, rather than to an unusual factor. Comprehensive income was ¥1.72B, exceeding consolidated net income of ¥1.44B. The primary reason was a ¥0.27B increase in valuation difference on securities, reflecting changes in asset value on a separate axis from core business profitability.
Progress toward the full-year plan (revenue of ¥165.40B, operating income of ¥8.98B, and ordinary income of ¥9.44B) was 24.5% for revenue, 23.1% for operating income, and 23.8% for ordinary income, all within a largely standard quarterly progress range of around 25%. While full-year operating income and ordinary income are forecast to decline 4.2% and 6.5%, respectively, from the previous year, earnings are progressing upward in the current quarter. This may indicate that the plan incorporates higher expenses and changes in the business environment toward the second half of the fiscal year. The earnings forecast and dividend forecast remain unchanged.
The full-year dividend forecast is ¥80 per share, including a ¥5 special dividend commemorating the company’s 70th anniversary. Based on the company’s projected EPS of ¥198.08, the payout ratio is approximately 40.4%. The robust financial foundation, including an equity ratio of 73.2% and cash and deposits of ¥26.54B, supports the dividend, which can be viewed as a sustainable level of shareholder returns. No disclosure regarding share buybacks was made this time, and dividends remain the primary means of shareholder returns.
Declining profitability at DispensingService: The operating margin declined to 1.9%, and operating income decreased 13.3% YoY. If the impact of the dispensing-fee and drug-price environment and rising costs continues, this could become a structural risk that puts pressure on the company-wide margin.
Concentration risk in the core business: HealthyLifeService accounts for 52.0% of the revenue mix and also makes a significant contribution to operating income. Changes in demand or the competitive environment for this business could have a relatively substantial impact on company-wide performance.
Heavy working capital: Accounts receivable of ¥23.59B and inventories of ¥6.79B are large in relation to the asset base, and short-term borrowings have also increased from the previous year. Although these are more than adequately covered by cash on hand of ¥26.54B, attention should be paid to increased funding requirements during periods of growth.
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 5.1% | 8.1% (2.3%–15.9%) | -3.0pt |
| Net Profit Margin | 3.6% | 5.9% (1.6%–10.7%) | -2.3pt |
Compared with the industry median, both the operating margin and net profit margin were lower, placing profitability at a relatively low level within the industry.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 3.6% | 9.3% (0.4%–16.9%) | -5.7pt |
Revenue growth also fell below the industry median, positioning the company conservatively in terms of growth.
※Source: Compiled by the Company
Operating income increased 11.5%, exceeding revenue growth of +3.6%, and the margin improved to 5.1%. Higher margins at HealthyLifeService and EcologyService supported the improvement in company-wide profitability.
The margin at DispensingService declined to 1.9%, partially offsetting the company-wide pace of earnings growth. Changes in the business’s cost structure and regulatory environment will be key to restoring profitability going forward.
Despite a robust financial foundation, including an equity ratio of 73.2% and cash of ¥26.54B, ROE remained low at 1.7%. The relationship between asset efficiency and capital efficiency will be an important area to monitor for future structural changes.
This is a mechanically calculated reference range based solely on publicly available data using a residual income model (Ohlson-type model with an explicit 5-year fade period). It is not a forecast of the market share price or a recommendation to take any specific investment action.
| Scenario | Theoretical Share Price |
|---|---|
| bear | ¥2,550 |
| base | ¥2,590 |
| bull | ¥2,638 |
| Calculation Assumption | Value |
|---|---|
| Book Value per Share (BPS) | ¥2,762 |
| Adjusted Forecast EPS | ¥207.7 |
| Cost of Equity r | 9.77% (10-year government bond 2.77% + equity risk premium 6.00% + size premium 1.00%) |
| Residual Income Persistence Coefficient ω / Explicit Forecast Period | 0.62 / 5 years |
| Assumed Payout Ratio | 40.4% |
| Forecast EPS Confidence Adjustment | ×1.049 (based on the historical guidance achievement rate of comparable companies) |
| Implied PBR / PER |
Sensitivity: ¥2,519–¥2,664 at ±1% for the cost of equity, and ¥2,584–¥2,594 at ±0.1 for ω.
Notes:
(Calculation model: Residual Income Model / Interest Rate Reference Month: 2026-07 / This value does not forecast or guarantee the future share price)
This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmark is reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional as necessary.
---End of Report---
| 0.94x / 12.5x |